# Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

> **NCT07524257** · PHASE3 · NOT_YET_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 494 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- Metastatic NSCLC

## Interventions

- **DRUG:** Drug: Nogapendekin alfa inbakicept (NAI)
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin or Carboplatin
- **DRUG:** Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous)
- **DRUG:** Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous)
- **DRUG:** Pemetrexed (nonsquamous)

## Key facts

- **NCT ID:** NCT07524257
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2029-05-15
- **Final completion:** 2029-12-30
- **Target enrollment:** 494 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07524257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07524257, "Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07524257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*